Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for ...
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage specialty biopharmaceutical company focused on therapies for retinal disease and other vision-related conditions. The company’s central purpose is to target critical pathways that underlie vision loss, aiming to slow, stop, or restore functional vision. Its approach is grounded in developing drug candidates ...Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage specialty biopharmaceutical company focused on therapies for retinal disease and other vision-related conditions. The company’s central purpose is to target critical pathways that underlie vision loss, aiming to slow, stop, or restore functional vision. Its approach is grounded in developing drug candidates designed specifically for ophthalmic biology and for delivery through eye-focused modalities such as oral/systemic small molecules and ocular formulations.
From a business perspective, Kiora operates primarily as an R&D-driven organization, where value creation depends on clinical progress, regulatory milestones, and the credibility of its clinical data packages. With a small operating footprint (reported full-time employees: 13), the company’s model relies on external expertise and partnerships typical of early-stage development companies—such as clinical research organizations, contract manufacturing, clinical sites, and specialized ophthalmology research resources.
In terms of products and pipeline, Kiora’s flagship candidate is KIO-301, a “photoswitch” small molecule being studied in Phase 1 clinical trials. The therapy is intended to revitalize vision in individuals suffering from inherited and age-related retinal degeneration. Additional pipeline assets include KIO-101, an eye drop in Phase 2 trials for ocular manifestations of rheumatoid arthritis and non-infectious posterior uveitis, as well as KIO-201, an eye drop in Phase 3 clinical trials intended to support corneal wound healing following PRK surgery. Collectively, these programs reflect a strategy that spans multiple ophthalmic indications and development stages, which can diversify clinical and regulatory risk relative to a single-asset company.
Cost and “BOM” considerations for a company like Kiora are heavily influenced by manufacturing scale, formulation development, analytical testing, and the logistics of clinical supply for ophthalmic drugs (sterility, stability, packaging, and lot control). Larger spending typically occurs in clinical trial execution (site monitoring, patient recruitment, safety monitoring, and data management), along with nonclinical/toxicology work required for regulatory filings.
Financially, the company’s provided valuation and profitability indicators (e.g., negative return metrics such as ROA and ROE in the latest TTM snapshot, and negative operating/FCF-related measures) are consistent with a development-stage biotech that is investing ahead of revenue generation. In such contexts, liquidity, working capital management, and access to capital markets or financing partners are key determinants of runway. The company’s current ratio and working capital metrics suggest a focus on maintaining sufficient resources to fund ongoing clinical programs.
Key leadership centers on Brian M. Strem, PhD, who serves as President and Chief Executive Officer. As the company advances its clinical programs, success criteria likely include maintaining trial enrollment and endpoints, demonstrating safety and efficacy signals across indications, and building toward potential regulatory submissions and commercialization pathways.
Looking ahead, Kiora’s near-term priorities are expected to include progressing clinical trials to readouts, supporting data generation for subsequent regulatory steps, and strengthening the operational and financial foundation needed to sustain development across multiple assets.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
-100.0%
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-10.8M
-401.4%
+62.9%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-10.1M
-217.8%
+39.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
2.3%
+928.9%
-26.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
5.99x
+21.1%
+34.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
